Compare ACV & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | BCYC |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 291.8M |
| IPO Year | N/A | 2019 |
| Metric | ACV | BCYC |
|---|---|---|
| Price | $26.45 | $4.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 36.9K | ★ 286.7K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.94 | $3.75 |
| 52 Week High | $29.04 | $9.16 |
| Indicator | ACV | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 58.92 |
| Support Level | $26.43 | $4.25 |
| Resistance Level | $26.80 | $4.51 |
| Average True Range (ATR) | 0.48 | 0.14 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 30.53 | 71.09 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.